NEWS
Advancements in Patient-Centered Care
Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.
BIDEN MOONSHOT INITIATIVE FOCUSED ON CHANGING CANCER LANDSCAPE
September 13, 2022 |
FOR IMMEDIATE RELEASE September 13, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org On the afternoon of Monday, September 12, President Biden arrived in Boston and made his way to the John F. Kennedy (JFK) Presidential Library. His visit […]
read more
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
September 12, 2022 |
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement August 26, 2022 – This marks the second indication for Pemazyre, which received accelerated FDA approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor […]
read more
SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022
September 12, 2022 |
SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 – Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints – – NDA Submission to the U.S. FDA […]
read more
MAINE CONTINUES REFORM FOR PATIENTS
September 6, 2022 |
FOR IMMEDIATE RELEASE September 6, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org In two consecutive legislative sessions in 2021 and 2022, the state of Maine has focused on reform for patients battling cancer. The legislative bodies in Maine […]
read more
Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)
August 26, 2022 |
New Approval Alert The U.S. Food and Drug Administration approved the use of IMBRUVICA® (ibrutinib) for the treatment of pediatric patient one year and older with cGvHD after failure of one or more lines of systemic therapy. Official statement HERE.
read more
Defining Appropriate Quality Performance Metrics for Pharmacies Dispensing Oral Oncology Therapies
August 19, 2022 |
NCODA applauds the recent published article in the American Journal of Managed Care® by our members at Florida Cancer Specialists and Research Institute titled “Defining Appropriate Quality Performance Metrics for Pharmacies Dispensing Oral Oncology Therapies.” Click the link below to read this article: https://www.ajmc.com/view/defining-appropriate-quality-performance-metrics-for-pharmacies-dispensing-oral-oncology-therapies
read more
NCODA and Florida Cancer Specialists & Research Institute Announce New Oncology Stakeholder Education Exchange Program
August 16, 2022 |
Cazenovia, NY, August 16, 2022 – New cancer treatment therapies, technologies and innovations continue to be discovered and approved for use at a rapid pace, creating an education challenge for physicians and other healthcare professionals within the complex oncology landscape. Working collaboratively with Florida Cancer Specialists & Research Institute, LLC (FCS), NCODA, Inc. developed a […]
read more
Cazenovia nonprofit to host ‘Passion Fore Patients’ Golf Tournament
August 9, 2022 |
Cazenovia nonprofit to host ‘Passion Fore Patients’ Golf Tournament
read more
Financial Impact of Medically Integrated Pharmacy Interventions on Oral Oncolytic Prescriptions
August 2, 2022 |
The NCODA CAWT Tool was recently published in the Journal of Clinical Oncology – Oncology Practice. The article highlights the medication waste associated with external specialty pharmacies compared to Medically Integrated Pharmacies (MIPs), as well as increased cost avoidance demonstrated by MIP teams. As the utilization of oral cancer medications rises, it is vital that cancer centers track costs associated with […]
read more
NCODA Announces New Education Platform for the Medically-Integrated Oncology Community
July 27, 2022 |
NCODA University Offers Complimentary Accredited Learning Through Virtual and In-Person Events CAZENOVIA, NY, July 27, 2022 – Empowering all stakeholders in oncology with easily accessible, patient-centered education and collaborative learning opportunities is fundamental to NCODA, Inc. Today, NCODA, launches NCODA University, a new division of the organization, which will allow medically-integrated oncology professionals to obtain […]
read more
Florida Takes Action Against Prescription Drug Pricing
July 14, 2022 |
FOR IMMEDIATE RELEASE July 14, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org Florida Takes Action Against Prescription Drug Pricing NCODA is proud to share that on July 8, 2022, Florida Governor Ron DeSantis issued Executive Order 22-164 […]
read more
Three Oncology Leaders Join NCODA Executive Council
July 7, 2022 |
FOR IMMEDIATE RELEASE July 7, 2022 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629 CAZENOVIA, NY – NCODA is pleased to announce the appointment of three oncology leaders to the Executive Council: Meg Butler, PharmD (Clearview Cancer Institute), Gury Doshi, MD (Texas Oncology), and Xylina Gregg, MD (Utah Cancer Specialists). “Our Executive Council is comprised of a […]
read more
NCODA International Abstract Published in Croatian Journal of Oncology
July 5, 2022 |
NCODA recently published an abstract titled “The NCODA PQI: Educating Your Medically Integrated Team While Supporting Better Patient Care with a Concise, Peer-Reviewed,Pharmacy-Led Resource” in the Croatian Journal of Oncology. This abstract is based on a presentation that our Founder & Executive Director, Michael Reff, RPh, MBA, delivered at the Croatian Virtual Congress of Oncology Pharmacy. Click HERE […]
read more
NCODA’s Legislative & Policy Advisory Committee Adds Top Thought Leaders in Oncology
June 30, 2022 |
FOR IMMEDIATE RELEASE June 30, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org NCODA Legislative & Policy Advisory Committee Adds Top Thought Leaders in Oncology NCODA is pleased to announce that Debra Patt, MD, PhD, MBA, Executive Vice […]
read more
RECENTLY PUBLISHED: ASCO/NCODA Standards Show Positive Benefit in Community Pharmacy
June 16, 2022 |
NCODA members from a community pharmacy in Canada recently published an article in the Journal of Oncology Pharmacy Practice that aimed to characterize their alignment with the ASCO/NCODA Standards and describe its impact on CDK4/6i treatment use. The authors concluded that a structured, patient-centered pharmacy practice model integrating the ASCO/NCODA Standards ensures timely medication refills, close monitoring, and allows […]
read more
OKLAHOMA RECOGNIZES PHARMACISTS AS ESSENTIAL COMMUNITY PROVIDERS
June 10, 2022 |
FOR IMMEDIATE RELEASE STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org OKLAHOMA RECOGNIZES PHARMACISTS AS ESSENTIAL COMMUNITY PROVIDERS NCODA applauds the recent efforts of the Oklahoma Legislature that passed HB 2322. This law recognizes pharmacists as Essential Community Providers […]
read more
NCODA Announces New Legislative & Policy Advisory Committee (LPAC) Member, Barbara McAneny, MD, FASCO, MACP
June 2, 2022 |
NCODA is proud to announce that Barbara McAneny, MD, FASCO, MACP will be joining our Legislative & Policy Advisory Committee (LPAC). Dr. McAneny is the CEO of New Mexico Oncology Hematology Consultants. Dr. McAneny was also elected by the American Medical Association House of Delegates and served as AMA President from 2018 – 2019. “NCODA […]
read more
WASHINGTON STATE ENDS LEGISLATIVE SESSION WITH WIN FOR PATIENTS
April 20, 2022 |
April 20, 2022 FOR IMMEDIATE RELEASE STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org WASHINGTON STATE ENDS LEGISLATIVE SESSION WITH WIN FOR PATIENTS The state of Washington wrapped up their legislative session with a huge victory for patients. Senate […]
read more
NCODA and XIFIN Launch New Initiative to Expand Oncology Patient Care Options
April 14, 2022 |
NCODA and XIFIN Launch New Initiative to Expand Oncology Patient Care Options “NCODA Informatics Initiative Powered by VisualStrata” Helps Attract Clinical Trials for Oncology Practices and Bridges the Gap with Pharmaceutical Organizations San Diego, CA and Cazenovia, NY April 14, 2022 – XIFIN has partnered with NCODA, Inc., a globally recognized association that develops unique […]
read more
OHIO MAKES IT OFFICIAL: UNANIMOUS VICTORY TO BAN COPAY ACCUMULATORS
April 6, 2022 |
FOR IMMEDIATE RELEASE April 6, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison (919) 903-2057 kevin.scorsone@ncoda.org www.ncoda.org OHIO MAKES IT OFFICIAL: UNANIMOUS VICTORY TO BAN COPAY ACCUMULATORS CAZENOVIA, NY – NCODA is proud to share the news that the Ohio House unanimously (86 to 0) […]
read more
NCODA Now Certified To Provide Continuing Education For Pharmacists & Pharmacy Technicians
March 29, 2022 |
FOR IMMEDIATE RELEASE March 29, 2022 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@NCODA.org 813-843-1629 NCODA Now Certified To Provide Continuing Education For Pharmacists & Pharmacy Technicians CAZENOVIA, NY – NCODA, a professional association dedicated to empowering the medically-integrated oncology community through leadership, quality standards, and best practices, is now certified by the Accreditation Council for […]
read more
Oral Oncolytic Non-Adherence in Medically Integrated Dispensing Pharmacies
March 24, 2022 |
The challenges associated with medication adherence and the negative impacts of non-adherence have been well documented. Medication adherence affects many aspects of public health, including, but not limited to, quality of life, patient outcomes, and overall healthcare costs.1 It is generally accepted that adherence rates of more than 80% are needed for optimal therapeutic efficacy.2 […]
read more
Oral Oncolytic Care Plans in Medically Integrated Dispensing Pharmacies
March 24, 2022 |
The development and utilization of oral oncolytics has steadily increased over the past 20 years. There are over 800 new oncology therapies in the drug development pipeline, 25%-35% of which are oral agents.1 The use of oral oncolytics presents unique challenges to patient safety compared to intravenous cancer treatments. As oral oncolytics are self-administered, it […]
read more
First-Of-Its-Kind Oncology State Legislation Tracking Tool
March 15, 2022 |
FOR IMMEDIATE RELEASE March 15, 2022 MEDIA CONTACT: Stephen Ziter Stephen.Ziter@ncoda.com 518-867-5001 First-Of-Its-Kind Oncology State Legislation Tracking Tool NCODA Launches a New Comprehensive Resource to Allow Oncology Healthcare Professionals to Stay Updated on the Latest in Relevant Policy/Legislation in all 50 States CAZENOVIA, NY – Today, NCODA announces the launch of its new and […]
read more
CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia
March 1, 2022 |
– VONJO is the First Approved Therapy to Specifically Address the Needs of Adult Cytopenic Myelofibrosis Patients – NDA Approved Under Priority Review – Approval Triggers $60 Million Payment from DRI Healthcare Trust – CTI to Host Conference Call Tomorrow at 8:00 a.m. ET SEATTLE, Feb. 28, 2022 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. […]
read more
Federal Trade Commission Seeking Information on How PBMs Impact Practices and Patients
February 25, 2022 |
FOR IMMEDIATE RELEASE STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison (919) 903-2057 kevin.scorsone@ncoda.org www.ncoda.org Federal Trade Commission Seeking Information on How PBMs Impact Practices and Patients On February 24, 2022, the Federal Trade Commission (FTC) announced that they are soliciting public input on the […]
read more
PBM REFORM BILL MAKING STRIDES IN VIRGINIA HOUSE OF REPRESENTATIVES
February 25, 2022 |
FOR IMMEDIATE RELEASE STATEMENT FROM NCODA’S LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org PBM REFORM BILL MAKING STRIDES IN VIRGINIA HOUSE OF REPRESENTATIVES In recent weeks, NCODA has been closely following and applauding PBM reform along with new provisions regarding patient copayments. […]
read more
OVERWHELMING CONSENSUS IN HOUSE PUTS PBM BILL ON DOORSTEP
February 18, 2022 |
February 18, 2022 FOR IMMEDIATE RELEASE STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org OVERWHELMING CONSENSUS IN HOUSE PUTS PBM BILL ON DOORSTEP A Comprehensive PBM Reform Bill is on the Desk of Michigan Gov. Gretchen Whitmer Awaiting […]
read more
NCODA Stands United With Biden Administration On Cancer Moonshot
February 17, 2022 |
Contact: Katie Edmiston | Marketing Manager NCODA, Inc. (813) 843-1629 Katie.Edmiston@ncoda.org February 17, 2022 NCODA Stands United with Biden Administration on Cancer Moonshot (CAZENOVIA, NY) – NCODA has always been committed to empowering the medically integrated oncology team to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards and best practices. […]
read more
Neratinib (Nerlynx®) Diarrhea Management
February 16, 2022 |
Written by: Eric Dallara, RPh, New England Cancer Specialist Download Here Description: Diarrhea is the main toxicity of neratinib treatment occurring in 95% of patients in the ExteNET trial on the neratinib arm in which antidiarrheal prophylaxis was not protocol specified.1 Various prevention and treatment strategies for diarrhea have been studied and will be discussed […]
read more
New NDC number for TIBSOVO®
February 15, 2022 |
Beginning February 14, 2022, there is a new NDC number for TIBSOVO® (72694-0617-60)*, the old NDC number was 71334-0100-01. SERVIER has new product packaging. The product itself remains the same. Listed below are pictures of the updated product packaging and ordering information. Updated Product Ordering Information: Description Strength/Size Supplier New NDC # TIBSOVO® (ivosidenib tablets) 250 mg tablet […]
read more
Fam-Trastuzumab deruxtecan-nxki (Enhertu®) Management
February 4, 2022 |
Written by: Brandy Persson, PharmD, BCPS, BCOP and Rebecca Fanning, PharmD, BCPS, Cone Health Download Here Description: Fam-trastuzumab deruxtecan-nxki is indicated for the treatment of: Adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with two or more anti-HER2-based regimens.1,2 This indication is under accelerated approval based […]
read more
Durvalumab (Imfinzi®) Therapy Overview
February 4, 2022 |
Written by: Joshua Nubla, PharmD, NCODA Download Here Description: The purpose of this PQI is to discuss the overall management of durvalumab and immune-mediated adverse events in the treatment of Stage III unresectable NSCLC and first-line extensive stage small cell lung cancer. Background: Durvalumab is a PD-L1 blocking monoclonal antibody and immune checkpoint inhibitor indicated […]
read more
Duvelisib (Copiktra®) for Chronic Lymphocytic Leukemia and Follicular Lymphoma
February 1, 2022 |
Written by: Linda Frisk, PharmD, Ironwood Cancer and Research Centers Download Here Description: The purpose of this PQI is to provide background on PI3K inhibition and review clinical considerations for duvelisib therapy in order to optimize outcomes for cancer patients as well as identifying the patients with malignant lymphoma who may be candidates for duvelisib. […]
read more
Selinexor (Xpovio®) Patient Management
February 1, 2022 |
Written by: Jeremiah Moore, PharmD, University of Rochester Medical Center Download Here Description: This PQI will provide background on the novel medication selinexor for patients with multiple myeloma (MM) who have received at least one prior therapy, relapsed, refractory multiple myeloma (RR-MM), and relapsed, refractory diffuse large b-cell lymphoma (RR-DLBCL) and discuss effective practices to […]
read more
Use of Isatuximab-irfc (Sarclisa®) in Patients with Relapsed Refractory Multiple Myeloma
January 28, 2022 |
Written by: Jon Suyko, PharmD, BCPS UCHealth Highlands Ranch Download Here Description: The purpose of this PQI is to discuss the option of using isatuximab-irfc (Sarclisa) for multiple myeloma patients who have been refractory to one to three prior lines of therapy or have had two prior treatment therapies including treatment with lenalidomide and a […]
read more
Tivozanib (Fotivda®) for Relapsed or Refractory Advanced Renal Cell Carcinoma
January 18, 2022 |
Written By: Pedro C. Barata, MD, Tulane University DOWNLOAD HERE Description: The purpose of this PQI is to review the clinical considerations around the use of tivozanib (Fotivda®) for patients with relapse or refractory advanced renal cell carcinoma. Background: Tivozanib is a small molecule that inhibits the phosphorylation of vascular endothelial growth factor […]
read more
Enfortumab Vedotin-ejfv (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma
January 14, 2022 |
Written by: Andrew Ruplin, PharmD, Seattle Cancer Care Alliance Download Here The purpose of this PQI is to understand the management techniques and interventions when utilizing enfortumab vedotin.
read more
NCODA Welcomes New Executive Council Members
January 12, 2022 |
FOR IMMEDIATE RELEASE January 12, 2022 Contact: Katie Edmiston | Marketing Manager (813) 843-1629 Katie.Edmiston@ncoda.org NCODA WELCOMES NEW EXECUTIVE COUNCIL MEMBERS CAZENOVIA, NY – NCODA today announced the appointment of four new members to the Executive Council. With the growth of NCODA, the Executive Council has been instrumental in facilitating a strong path forward […]
read more
Temozolomide (Temodar®) for Glioblastoma Multiforme
January 4, 2022 |
Written By: Hassaan Shaikh, PharmD & Emily Brugioni, MD, University Health DOWNLOAD HERE Description: The purpose of this PQI is a summary of the process for initiating and monitoring oral temozolomide therapy in patients with Glioblastoma Multiforme (GBM). Background: GBM is the most common primary malignant brain tumor in adults and comprises 54 % of […]
read more
GOV. HOCHUL (NY) SIGNS BILL TO REGULATE PHARMACY BENEFIT MANAGERS
January 3, 2022 |
FOR IMMEDIATE RELEASE January 3rd 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org GOV. HOCHUL (NY) SIGNS BILL TO REGULATE PHARMACY BENEFIT MANAGERS Throughout 2021 NCODA highlighted states throughout the country that took great strides to regulate Pharmacy […]
read more
Ponatinib (Iclusig®) Patient Management
December 20, 2021 |
Written by: Jessie Signorelli PharmD, BCOP, Massachusetts General Hospital DOWNLAD HERE Description: This PQI will aim to review ponatinib efficacy and safety data as well as clinical pearls regarding supportive care and adverse event management.1 Background: Ponatinib (Iclusig®) is a third-generation tyrosine kinase inhibitor (TKI) with activity directed at BCR-ABL mutant kinase in patients with […]
read more
Managing EGFR Inhibitor Induced Rash
December 13, 2021 |
Written by: Sara Moran Smith, PharmD, BCOP | M Health Fairview DOWNLOAD HERE Purpose: Rash occurs in approximately 90% of patients treated with epidermal growth factor receptor (EGFR) inhibitors1 with 10-20% developing severe eruption.1 Studies have shown that the presence of this rash is indicative of response to treatment.1 Therefore, it is important to prevent […]
read more